Singer Barak 4
4 · OphthaliX, Inc. · Filed May 8, 2013
Insider Transaction Report
Form 4
OphthaliX, Inc.OPLI
Singer Barak
Chief Executive Officer
Transactions
- Award
Options
2013-04-22$1.18/sh+469,854$552,407→ 469,854 totalExercise: $1.18Exp: 2023-04-21→ Common Stock (469,854 underlying) - Award
Options
2013-04-22$1.18/sh+469,854$552,407→ 939,708 totalExercise: $1.18Exp: 2023-04-21→ Common Stock (469,854 underlying)
Footnotes (2)
- [F1]Options shall vest over a period of three years on a quarterly basis over twelve consecutive quarters from the date of commencement of the employment of Mr. Singer with the Company (February 28, 2013).
- [F2]Options shall vest upon the achievement of the following milestones by the Company (the "Success Based Options"): 156,618 options representing one third of the Success Based Options to vest upon the commencement of the trading of the Company's securities on Nasdaq or NYSE MKT LLC; 156,618 options representing the remaining third of the Success Based Options to vest upon the commencement of a phase 3 clinical trial of CF-101 for Glaucoma (and in the unlikely event that the phase 2 trial is unsuccessful, then the Board of Directors will allocate a different milestone).